1 Institute of Ageing & Chronic Disease, University of Liverpool, UK.
2 Liverpool Vascular & Endovascular Service, Royal Liverpool Hospital, Liverpool, UK.
J Endovasc Ther. 2017 Dec;24(6):773-778. doi: 10.1177/1526602817728069. Epub 2017 Sep 12.
To determine how many endovascular aneurysm sealing (EVAS) procedures with/without off-label use of chimneys (ChEVAS) could have been performed in a cohort of patients who had undergone fenestrated endovascular aneurysm repair (FEVAR).
Sixty patients (median age 76.3 years; 54 men) who underwent FEVAR in our institution between 2013 and 2015 were selected for the study. The median aneurysm diameter was 62.0 mm (interquartile range 59.3, 69.0). Preoperative computed tomography angiograms (CTA) were anonymized and sent to 2 physicians with experience of more than 40 ChEVAS interventions. These ChEVAS planners were blinded to the study purpose and asked to agree upon an EVAS/ChEVAS plan. The primary outcome was the percentage of the FEVAR patients in whom an EVAS/ChEVAS was technically possible. The secondary outcomes were a comparison of seal zones, number of target vessels, and device cost.
An EVAS-based intervention would have been technically possible in 56 (93.3%) of the FEVAR patients. The median proximal aortic seal zone was significantly more distal in the EVAS/ChEVAS procedures vs the FEVAR cases (zone 8 vs zone 7, p<0.001) and fewer target vessels were involved (median 2 vs 3, p<0.001). The cost of the EVAS/ChEVAS device was 66% of the FEVAR device. Planners would not currently advocate an EVAS-based intervention in 43 (76.8%) of these 56 patients due to concerns regarding the risk of migration associated with the lumen thrombus ratios observed.
EVAS is technically feasible in the majority of patients undergoing FEVAR in our institution but currently advocated in only 23.2%. The seal zone was more distal, fewer target vessels were involved, and the device cost was lower in the planned EVAS/ChEVAS interventions.
确定在接受开窗血管内动脉瘤修复术(FEVAR)的患者队列中,可以进行多少例带/不带 Chimneys(ChEVAS)的血管内动脉瘤密封(EVAS)手术。
选择 2013 年至 2015 年期间在我院接受 FEVAR 的 60 例患者(中位年龄 76.3 岁;54 名男性)进行研究。中位动脉瘤直径为 62.0 毫米(四分位间距 59.3,69.0)。术前计算机断层血管造影(CTA)进行匿名化处理,并发送给 2 位具有超过 40 例 ChEVAS 干预经验的医生。这些 ChEVAS 计划者对研究目的不知情,并被要求就 EVAS/ChEVAS 计划达成一致。主要结局是在 FEVAR 患者中,EVAS/ChEVAS 在技术上可行的百分比。次要结局是比较密封区、目标血管数量和设备成本。
在 56 例(93.3%)FEVAR 患者中,EVAS 为基础的干预在技术上是可行的。EVAS/ChEVAS 手术的近端主动脉密封区明显比 FEVAR 病例更靠远端(区 8 与区 7,p<0.001),涉及的目标血管更少(中位 2 与 3,p<0.001)。EVAS/ChEVAS 设备的成本为 FEVAR 设备的 66%。由于对观察到的管腔血栓比相关的迁移风险的担忧,计划者目前不会在这 56 例患者中的 43 例(76.8%)中推荐基于 EVAS 的干预。
在我院接受 FEVAR 的大多数患者中,EVAS 在技术上是可行的,但目前仅推荐 23.2%。在计划的 EVAS/ChEVAS 干预中,密封区更靠远端,涉及的目标血管更少,设备成本更低。